Men C vaccine is safe for infants

October 21, 2001

A Men C vaccine, introduced into the UK immunisation schedule two years ago is safe, with minimal side effects, reports a study in the Archives of Disease in Childhood.

Concerns were raised about possible adverse side effects when these vaccines were first introduced because only one large scale safety study had been reported.

The researchers monitored adverse events after Men C vaccination in almost 3000 infants between the ages of 2 and 5 months. The children were recruited by general practitioners in the North Trent Region and Scotland.

They received all the routine vaccines at 2, 3, and 4 months, as well as Men C. All adverse events requiring medical attention and occurring within a month of each injection were recorded, including common childhood illnesses and injuries.

Adverse events were reported for almost two thirds of the children, but most were mild and thought to be unrelated to the vaccine. No serious adverse events were thought to be possibly or definitely associated with the vaccine.

Four serious events occurred, including brief loss of muscle tone (hypotonia), inconsolable screaming for a few hours, rash, and agitation. All these are know to occur occasionally after the other vaccines the children received. In all cases, the children made a full recovery.

The only adverse events thought to be definitely related to Men C vaccine were injection site reactions of swelling and redness, which five infants had.

Large scale effectiveness and safety studies are the norm before the introduction of a new vaccine, but the sheer logistics, timing, and cost made this difficult in the case of Men C. Similar dilemmas about how best to establish safety are likely to arise again as more childhood vaccines against rare but serious diseases are developed, they conclude.
-end-
[Safety of a new conjugate meningococcal C vaccine in infants 2001; 85:391-7]

BMJ Specialty Journals

Related Vaccines Articles from Brightsurf:

Comprehensive safety testing of COVID-19 vaccines based on experience with prior vaccines
'The urgent need for COVID-19 vaccines must be balanced with the imperative of ensuring safety and public confidence in vaccines by following the established clinical safety testing protocols throughout vaccine development, including both pre- and post-deployment,' write David M.

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.

Model could improve design of vaccines, immunotherapies
Researchers have discovered a general property for understanding how immune cell receptors sense and respond to microbial signals, which could lead to more effective vaccines for both existing and novel viruses.

Better vaccines are in our blood
Red blood cells don't just shuttle oxygen from our lungs to our organs: they also help the body fight off infections by capturing pathogens in the blood and presenting them to immune cells in the spleen.

Challenges in evaluating SARS-CoV-2 vaccines
With more than 140 SARS-CoV-2 vaccines in development, the race is on for a successful candidate to help prevent COVID-19.

Designing vaccines from artificial proteins
EPFL scientists have developed a new computational approach to create artificial proteins, which showed promising results in vivo as functional vaccines.

Misinformation on vaccines readily available online
Parents researching childhood vaccinations online are likely to encounter significant levels of negative information, researchers at the University of Otago, Wellington, have found.

Battle with the cancer: New avenues from childhood vaccines
A new research from the University of Helsinki showed for the first time how the pre-immunization acquired through common childhood vaccines can be used to enhance therapeutic cancer treatment.

Personalized cancer vaccines
The only therapeutic cancer vaccine available on the market has so far showed very limited efficacy in clinical trials.

Doubts raised about effectiveness of HPV vaccines
A new analysis of the clinical trials of HPV vaccines to prevent cervical cancer raises doubts about the vaccines' effectiveness.

Read More: Vaccines News and Vaccines Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.